<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543478</url>
  </required_header>
  <id_info>
    <org_study_id>SB</org_study_id>
    <secondary_id>URC 071006MED</secondary_id>
    <nct_id>NCT00543478</nct_id>
  </id_info>
  <brief_title>Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome</brief_title>
  <acronym>SBIBS</acronym>
  <official_title>Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probiotics are friendly bacteria normally present in food products like yogurt whereas&#xD;
      irritable bowel syndrome is a longstanding functional disorder characterized by abdominal&#xD;
      pain and altered bowel habits either diarrhea or constipation dominant without a definitive&#xD;
      etiology.&#xD;
&#xD;
      Study Hypothesis:Does probiotics(Saccharomyces boulardii improves daily bowel symptoms and&#xD;
      quality of life in patients with diarrhea dominant irritable bowel syndrome?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) is a common functional disorder and may lead to impaired&#xD;
      social and personal function and can diminish quality of life.While the precise&#xD;
      pathophysiology of IBS remains to be elucidated, dysmotility and altered visceral sensory&#xD;
      perception are currently the most popular hypothesis. There has been a suggestion that some&#xD;
      patients with IBS may harbor bacterial overgrowth leading to low grade inflammation, immune&#xD;
      activation, and their symptoms may be ameliorated by its eradication.Probiotics, defined as&#xD;
      live or attenuated bacteria or micro organism that confer a significant health benefit to the&#xD;
      host.&#xD;
&#xD;
        -  I. Firstly, probiotic organism exert antibacterial and antiviral effects.&#xD;
&#xD;
        -  II. Probiotics could alter the composition of the gut flora, either directly through&#xD;
           augmentation of commensal or indirectly through a reduction in pathogen related&#xD;
           inflammation or bacterial fermentation.&#xD;
&#xD;
      Trial protocol:&#xD;
&#xD;
      Phase 1: placebo BID (1 week),both arms Phase 2: Randomization by pharmacy, placebo vs.&#xD;
      active drug (6 weeks) Phase 3: placebo BID (1 week), both arms&#xD;
&#xD;
      -III. Probiotics have been demonstrated to exert anti-inflammatory effects at mucosal&#xD;
      surfaces by reducing mucosal inflammation, decreasing immune mediated activation of enteric&#xD;
      motor and sensory neurons and modifying neural traffic between the gut and central nervous&#xD;
      system.&#xD;
&#xD;
      Saccharomyces Boulardii is a probiotic yeast and its role for the treatment of IBS has not&#xD;
      been extensively investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Improvement in symptoms of number of bowel habits, urgency, straining,sense of incomplete evacuation, stool form (evaluated by Bristol stool form scale, abdominal pain and bloating/flatulence</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life in diarrhea dominant IBS by validated IBS-QOL questionnaire.</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given twice a day for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>250mg, twice a day in sachets, for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl cellulose powder (low viscosity)</intervention_name>
    <description>twice a day sachets for 10 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be recruited from gastroenterology clinic at Aga Khan University&#xD;
             hospital with diagnosis of diarrhea dominant irritable syndrome.&#xD;
&#xD;
          -  Age between 18- 60 years.&#xD;
&#xD;
          -  Male and female both.&#xD;
&#xD;
          -  Organic gastrointestinal diseases excluded by baseline laboratory and&#xD;
             sigmoidoscopy/colonoscopy and biopsy within last 2 years.&#xD;
&#xD;
          -  All Patients need to satisfy ROME III criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 and &gt; 60 years&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  Patients on laxatives or antidiarrheal drugs that could influence the motility of gut&#xD;
&#xD;
          -  Patient on antibiotics or within 2 weeks of starting protocol.&#xD;
&#xD;
          -  Not willing to participate&#xD;
&#xD;
          -  Non-compliant in run in period.&#xD;
&#xD;
          -  Patients taking Husk.&#xD;
&#xD;
          -  Diabetic patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubna Kamani, FCPS,MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lubna Kamani, FCPS, MRCP</last_name>
    <phone>9221-4864659</phone>
    <email>lubna.kamani@aku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology outpatients clinics,Aga Khan University hospital</name>
      <address>
        <city>Karachi.</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubna Kamani, FCPS,MRCP</last_name>
      <phone>9221-4864659</phone>
      <email>lubna.kamani@aku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wasim Jafri, FRCP</last_name>
      <phone>9221-4864661</phone>
      <email>wasim.jafri@aku.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lubna Kamani, FCPS,MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 12, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>October 12, 2007</last_update_submitted>
  <last_update_submitted_qc>October 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2007</last_update_posted>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

